Our team developed a rapid, versatile “plug-and-play” pseudotyped virus neutralisation assay that allows scientists to measure immune responses to several dangerous bunyaviruses without needing high-containment (BSL-3/4) facilities.
This is a major step forward because:
- It accelerates vaccine and therapeutic evaluation — a key objective of the 100-Days Mission.
- It enables safe, standardised testing across laboratories worldwide.
- It can be quickly adapted to new or emerging viruses, supporting preparedness for Disease X.
🔍 Why it matters for CCHFVACIM
The CCHFVACIM project aims to advance vaccines and medical countermeasures against CCHFV. One of our biggest bottlenecks is the lack of fast, accessible tools to assess immune protection.
This newly published method answers exactly that need:
➡️ It produces high-quality pseudotyped particles for CCHFV within a few days.
➡️ It shows excellent correlation with neutralisation assays using authentic virus.
➡️ It can be used to evaluate vaccine candidates and convalescent responses — directly supporting the development pipeline of our consortium.
🎉 A big congratulations to all authors and collaborators!
This work strengthens not only the CCHFVACIM programme, but also the global capacity to respond to emerging viral threats.
📄 Article: A system to rapidly develop a bunyavirus pseudotyped virus neutralisation assay for pandemic preparedness (npj Vaccines, 2025).
